- Darunavir ethanolate
-
- $0.00 / 25Kg/Bag
-
2025-05-23
- CAS:635728-49-3
- Min. Order: 2Kg/Bag
- Purity: 0.0099
- Supply Ability: 20 tons
- Darunavir Ethanolate
-
- $31.00 / 5mg
-
2025-05-22
- CAS:635728-49-3
- Min. Order:
- Purity: 99.84%
- Supply Ability: 10g
- Darunavir ethanolate
-
- $0.00 / 25kg
-
2025-05-12
- CAS:635728-49-3
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 10000KGS
|
| | Darunavir ethanolate Basic information |
| Product Name: | Darunavir ethanolate | | Synonyms: | Unii-33o78xf0bw;N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester compd. with ethanol;Darunavir Ethanolate(Prezista);Darunavir(TMC-114,UIC 94017) Ethanolate;N-[(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl carbamic acid ester, compd. with ethanol (1:1);(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate compound with ethanol (1:1);[14C]-Darunavir ethanolate;DARUNAVIR ETHANOLATE (TMC114 ETHANOLATE) | | CAS: | 635728-49-3 | | MF: | C29H43N3O8S | | MW: | 593.74 | | EINECS: | | | Product Categories: | Inhibitor;Prezista, TMC114;Other APIs;Inhibitors;API | | Mol File: | 635728-49-3.mol |  |
| | Darunavir ethanolate Chemical Properties |
| Melting point | 98-100°C | | storage temp. | Refrigerator | | solubility | Chloroform (Slightly), Methanol (Slightly) | | form | Solid | | color | White |
| | Darunavir ethanolate Usage And Synthesis |
| Uses | Darunavir Ethanolate (Prezista) is an HIV protease inhibitor. Derivative of Darunavir (D193500), a second generation HIV-1-protease inhibitor; structurally similar to amprenavir. Antiviral. It is a COVID19-related research product. | | Uses | Darunavir Ethanolate(Prezista) is an inhibitor of HIV protease. [1] Darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including strains from treatment-experienced patients with multiple resistance mutati | | Biological Activity | darunavir ethanolate is a nonpeptidic hiv protease inhibitor approved for the treatment of hiv infection[1].transepithelial transport of darunavir in caco-2 cell monolayers is 2-fold greater in the basal-to-apical direction compared to that in the opposite direction. in l-mdr1 cell, darunavir (121 mm) inhibits p-glycoprotein-mediated efflux of calcein-acetoxymethyl ester[1].darunavir is effective against wild-type and pi-resistant hiv, and has a low oral bioavailability (37%). when used in combination with ritonavir, bioavailability can be increased to 82%[2].[1]. fujimoto h, higuchi m, watanabe h, et al. p-glycoprotein mediates efflux transport of darunavir in human intestinal caco-2 and abcb1 gene-transfected renal llc-pk1 cell lines. biological & pharmaceutical bulletin, 2009, 32(9): 1588-1593.[2]. bhalekar mr, et al. in-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir. drug deliv, 2016, 23(7): 2581-2586. | | in vivo | Darunavir is effective against wild-type and PI-resistant HIV, and has an oral bioavailability of 37%. It needs to be combined with ritonavir, which increases the bioavailability to 82%[3]. | | IC 50 | HIV-1 |
| | Darunavir ethanolate Preparation Products And Raw materials |
|